Procedure with SR18662 appreciably minimizes progress and proliferation of CRC cells. SR18662 reveals improved efficacy in lessening viability of many CRC cell strains. Movement cytometry Evaluation next SR18662 therapy demonstrates an increase in cells captured in both S or G2/M phases in the mobile cycle and a significant increase in the amount o